



# MONROE CAPITAL



## — LEADER IN MIDDLE MARKET HEALTHCARE FINANCE —

### INVESTMENT CRITERIA

- Middle market companies starting at \$5 million EBITDA

### INVESTMENT PRODUCTS

- Cash flow and enterprise value based loans
- Unitranche financings
- Club and syndicated investments
- Equity co-investments

### TRANSACTION TYPES

- Acquisitions
- Refinancings
- Bridge loans
- Growth capital
- Leveraged recapitalizations

### TARGET INVESTMENTS

- Private equity sponsored
- Privately held
- Women and minority-owned businesses
- Headquartered in the U.S. or Canada

### INDUSTRY VERTICALS

- Healthcare
- Technology
- Specialty Finance
- Retail and Consumer Products
- Media
- Employee Owned Stock Ownership Plans (ESOPs)

### HEALTHCARE SEGMENTS OF INTEREST

- Facility or home based services
- Provider practice management
- Pharmaceutical products and services
- Payor and provider outsourcing
- Medical staffing
- Niche medical products and equipment
- Specialty distribution
- Healthcare information technology
- Animal health

With over 1,275 transactions completed and more than \$10.5 billion in financings for middle market clients in the U.S. and Canada, Monroe Capital prides itself on its flexible investment approach and its ability to close and fund transactions quickly.



**2019** BEST U.S. DIRECT  
LENDING FUND of the YEAR



**2018** LOWER MID-MARKET  
LENDER of the YEAR, AMERICAS



**2018** LENDER  
of the YEAR



**2018** SMALL MIDDLE MARKETS  
LENDER of the YEAR, AMERICAS



**2015** SMALL BUSINESS INVESTMENT  
COMPANY (SBIC) of the YEAR

Chicago • New York • Los Angeles • San Francisco • Atlanta • Boston

monroecap.com | 312.258.8300

## HEALTHCARE FINANCE

### CONTACT

Matthew Evans  
 Managing Director, Head of Healthcare Finance  
 (312) 568-7806  
 mevans@monroecap.com

Tommy Ryan  
 Managing Director  
 (312) 598-8355  
 tryan@monroecap.com

<p><b>\$72,500,000</b> Senior Credit Facility</p> <p><i>was provided to support the acquisition of</i></p> <p><b>Niche Pharmacy Services Business</b></p> <p>by</p> <p><b>Private Equity Sponsor</b></p> <hr/> <p><b>Agent</b></p>	<p><b>Undisclosed</b> Senior Credit Facility</p> <p><i>was provided to support the acquisition of</i></p> <p><b>SMP PHARMACY SOLUTIONS</b></p> <p>by</p> <p><b>GALEN PARTNERS</b></p> <hr/> <p><b>Agent</b></p>	<p><b>\$32,700,000</b> Senior Credit Facility &amp; Equity Co-Investment</p> <p><i>was provided to support the recapitalization of</i></p> <p><b>HealthCare Strategies, Ltd.</b></p> <p>by</p> <p><b>LEVEL CAPITAL PARTNERS</b></p> <hr/> <p><b>Agent</b></p>	<p><b>Undisclosed</b> Senior Credit Facility</p> <p><i>was provided to support the future growth of</i></p> <p><b>CITIZENS</b></p> <hr/> <p><b>Agent</b></p>	<p><b>\$26,300,000</b> Senior Credit Facility</p> <p><i>was provided to refinance the existing debt facility and support an acquisition for</i></p> <p><b>AMERICAN OPTICS</b></p> <p>a portfolio company of</p> <p><b>DW HP</b></p> <hr/> <p><b>Agent</b></p>	<p><b>\$125,000,000</b> Senior Credit Facility</p> <p><i>was provided to support the recapitalization and a minority investment of a</i></p> <p><b>Healthcare Services Company</b></p> <p>a portfolio company of</p> <p><b>Riverside</b></p> <hr/> <p><b>Agent</b></p>
<p><b>Undisclosed</b> Unitranche Credit Facility</p> <p><i>was provided to support the future growth of</i></p> <p><b>PRIORITY AMBULANCE</b></p> <p>by</p> <p><b>ENHANCED EQUITY FUNDS</b></p> <hr/> <p><b>Agent</b></p>	<p><b>Undisclosed</b> Senior Credit Facility</p> <p><i>was provided to support the recapitalization of</i></p> <p><b>CAREPLUS</b></p> <p>by</p> <p><b>FULCRUM EQUITY PARTNERS</b></p> <p>and</p> <p><b>LEVEL CAPITAL PARTNERS</b></p> <hr/> <p><b>Agent</b></p>	<p><b>Undisclosed</b> Senior Credit Facility</p> <p><i>was provided to support the acquisition of</i></p> <p><b>PROPHARMA GROUP</b></p> <p>by</p> <p><b>LINDEN</b></p> <hr/> <p><b>Agent</b></p>	<p><b>Undisclosed</b> First Lien Facility</p> <p><i>was provided to support the recapitalization and growth of</i></p> <p><b>PIVOT PHYSICAL THERAPY</b></p> <p>by</p> <p><b>CI CAPITAL PARTNERS</b></p> <hr/> <p><b>Participant</b></p>	<p><b>\$63,000,000</b> Senior Credit Facility</p> <p><i>was provided to support an investment in</i></p> <p><b>FAMILY DENTAL</b></p> <p>by</p> <p><b>THE HALIFAX GROUP</b></p> <hr/> <p><b>Agent</b></p>	<p><b>Undisclosed</b> Senior Credit Facility</p> <p><i>was provided to support the acquisition of a</i></p> <p><b>Substance Abuse Treatment Provider</b></p> <hr/> <p><b>Agent</b></p>
<p><b>Undisclosed</b> Senior Credit Facility</p> <p><i>was provided to support the recapitalization of</i></p> <p><b>avadynehealth</b></p> <p>by</p> <p><b>MTS HEALTH INVESTORS</b></p> <hr/> <p><b>Syndication Agent</b></p>	<p><b>Undisclosed</b> Senior Credit Facility</p> <p><i>was provided to support the growth of</i></p> <p><b>Accelerated</b></p> <p>by</p> <p><b>OMERS Private Equity</b></p> <hr/> <p><b>Participant</b></p>	<p><b>\$22,500,000</b> Senior Term Loan Facility</p> <p><i>was provided to support the acquisition of</i></p> <p><b>EMSI</b></p> <p>by</p> <p><b>BECKEN PETER O'SHEE &amp; COMPANY</b></p> <hr/> <p><b>Agent</b></p>	<p><b>\$14,500,000</b> Senior Credit Facility</p> <p><i>was provided to support the recapitalization and growth of</i></p> <p><b>PRECISION TOXICOLOGY</b></p> <p>by</p> <p><b>BELHEALTH Investment Partners</b></p> <hr/> <p><b>Agent</b></p>	<p><b>\$38,600,000</b> Unitranche Credit Facility</p> <p><i>was provided to support the acquisition of</i></p> <p><b>Laboratory Testing Services Company</b></p> <p>by</p> <p><b>Private Equity Sponsor</b></p> <hr/> <p><b>Agent</b></p>	<p><b>\$30,000,000</b> Senior Credit Facility</p> <p><i>was provided to support the growth of a</i></p> <p><b>Diagnostic Services Company</b></p> <hr/> <p><b>Agent</b></p>
<p><b>\$20,000,000</b> Senior Credit Facility</p> <p><i>was provided to support the growth of</i></p> <p><b>Cytovance Biologics</b></p> <p>by</p> <p><b>One PM Partners, LLC</b></p> <hr/> <p><b>Agent</b></p>	<p><b>\$14,000,000</b> Senior Secured Credit Facility</p> <p><i>was provided to support the recapitalization and growth of</i></p> <p><b>STARPOINT HEALTH</b></p> <p>by</p> <p><b>Caltius Equity Partners</b></p> <hr/> <p><b>Agent</b></p>	<p><b>\$15,500,000</b> Senior Secured Credit Facility</p> <p><i>was provided to support the acquisition of</i></p> <p><b>Employee Benefit Solutions</b></p> <p>by</p> <p><b>PHAROS</b></p> <hr/> <p><b>Agent</b></p>	<p><b>\$75,000,000</b> Senior Secured Credit Facility</p> <p><i>was provided to support the growth of</i></p> <p><b>Alora Pharmaceuticals, LLC, parent company of</b></p> <p><b>Avion PHARMACEUTICALS</b></p> <p>by</p> <p><b>Acella PHARMACEUTICALS, LLC</b></p> <hr/> <p><b>Agent</b></p>	<p><b>\$16,600,000</b> Unitranche Credit Facility</p> <p><i>was provided to support the growth of</i></p> <p><b>smiles dental.</b></p> <p>by</p> <p><b>WAFRA</b></p> <hr/> <p><b>Agent</b></p>	<p><b>\$35,000,000</b> Unitranche Credit Facility and Equity Co-Investment</p> <p><i>was provided to support the growth and recapitalization of a</i></p> <p><b>Healthcare Services Provider</b></p> <p>by</p> <p><b>CENTREPARTNERS</b></p> <hr/> <p><b>Agent</b></p>